Literature DB >> 11393207

Corticosteroid-induced atrophy and barrier impairment measured by non-invasive methods in human skin.

L Kolbe1, A M Kligman, V Schreiner, T Stoudemayer.   

Abstract

BACKGROUND/AIMS: Atrophy is a distressing side effect of potent corticosteroids. After open application of a high potency steroid, we monitored atrophogenicity by a variety of non-invasive methods.
METHODS: Volar forearms were treated twice daily for 3 or 4 weeks, with clobetasol propionate cream (Temovate). The following methods were used: 1) confocal microscopy, 2) transepidermal water loss (TEWL), 3) dimethyl sulfoxide whealing, 4) sodium hydroxide erosions, 5) analysis of stratum corneum lipids, and 6) B-scan ultrasound.
RESULTS: Confocal microscopy revealed thinning of the epidermis, decreased microvasculature and decreased size of keratinocytes. Evaporimetry demonstrated transepidermal water loss. Whealing to dimethyl sulfoxide was enhanced. Sodium hydroxide erosions formed more quickly. The amount of ceramides, cholesterol, and free fatty acids was reduced. Ultrasound showed thinning of the dermis.
CONCLUSION: Non-invasive methods are very useful for quantifying the atrophogenicity of topical corticosteroids.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11393207     DOI: 10.1034/j.1600-0846.2001.70203.x

Source DB:  PubMed          Journal:  Skin Res Technol        ISSN: 0909-752X            Impact factor:   2.365


  36 in total

1.  Test systems for the determination of glucocorticoid receptor ligand induced skin atrophy.

Authors:  Stefanie Schoepe; Heike Schäcke; Khusru Asadullah
Journal:  Dermatoendocrinol       Date:  2011-07-01

2.  Fluorescence spectroscopy as a tool to detect and evaluate glucocorticoid-induced skin atrophy.

Authors:  Moyses Costa Lemos; Wagner Rafael Correr; Lucimar Retto da Silva de Avó; Carla Maria Ramos Germano; Cristina Kurachi; Igor Polikarpov; Débora Gusmão Melo
Journal:  Lasers Med Sci       Date:  2012-01-17       Impact factor: 3.161

3.  Dermacase. Atrophic patches.

Authors:  Patricia Ting; Benjamin Barankin
Journal:  Can Fam Physician       Date:  2006-12       Impact factor: 3.275

Review 4.  [Lupoid perioral dermatitis as a special form of perioral dermatitis: review of pathogenesis and new therapeutic options].

Authors:  J Baratli; M Megahed
Journal:  Hautarzt       Date:  2013-12       Impact factor: 0.751

5.  Topical hesperidin prevents glucocorticoid-induced abnormalities in epidermal barrier function in murine skin.

Authors:  George Man; Theodora M Mauro; Peggy L Kim; Melanie Hupe; Yongjiao Zhai; Richard Sun; Debbie Crumrine; Carolyn Cheung; Almudena Nuno-Gonzalez; Peter M Elias; Mao-Qiang Man
Journal:  Exp Dermatol       Date:  2014-07-31       Impact factor: 3.960

Review 6.  Therapeutic Benefits of Natural Ingredients for Atopic Dermatitis.

Authors:  George Man; Li-Zhi Hu; Peter M Elias; Mao-Qiang Man
Journal:  Chin J Integr Med       Date:  2017-09-01       Impact factor: 1.978

7.  Chinese herbal medicine (Tuhuai extract) exhibits topical anti-proliferative and anti-inflammatory activity in murine disease models.

Authors:  Mao-Qiang Man; Yuejun Shi; Mona Man; Seung Hun Lee; Marianne Demerjian; Sandra Chang; Kenneth R Feingold; Peter M Elias
Journal:  Exp Dermatol       Date:  2008-03-13       Impact factor: 3.960

8.  Occupational skin diseases: options for multidisciplinary networking in preventive medicine.

Authors:  Swen Malte John
Journal:  Ger Med Sci       Date:  2008-10-27

9.  Longitudinal in vivo tracking of adverse effects following topical steroid treatment.

Authors:  Andrew J Bower; Zane Arp; Youbo Zhao; Joanne Li; Eric J Chaney; Marina Marjanovic; Angela Hughes-Earle; Stephen A Boppart
Journal:  Exp Dermatol       Date:  2016-02-13       Impact factor: 3.960

10.  Tertiary individual prevention of occupational skin diseases: a decade's experience with recalcitrant occupational dermatitis.

Authors:  C Skudlik; B Wulfhorst; G Gediga; M Bock; H Allmers; S M John
Journal:  Int Arch Occup Environ Health       Date:  2008-02-01       Impact factor: 3.015

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.